CD274 and leukemia: There is not only a need for highly specific and stable monoclonal antibodies and small molecule inhibitors but also investigations of the additional nonoverlapping immunosuppressive mechanisms akin to the CD73/adenosine and PD1/PDL1 pathways to enhance the survival rates of patients with leukemia and other cancers.